Weight Regain After Stopping GLP-1: What Trials Found

Weight regain is common after stopping GLP-1-based treatment, but the amount varies. The often-quoted “two-thirds” figure comes from one semaglutide study's average recovery of previously lost weight. It does not mean everyone regains two-thirds of their total body weight, or that regain is inevitable to the same degree for every person.

Two withdrawal studies, different measurements

Study	Before withdrawal	What happened afterward
STEP 1 extension: semaglutide 2.4 mg	The semaglutide extension group lost an average 17.3% of baseline weight over 68 weeks	During the next year, 11.6 percentage points of baseline weight returned; average net loss remained 5.6%
SURMOUNT-4: tirzepatide	Participants lost an average 20.9% during a 36-week lead-in	Over the next 52 weeks, switching to placebo produced a 14.0% increase from week-36 weight; continuing tirzepatide produced a further 5.5% decrease

Sources: STEP 1 extension and SURMOUNT-4. The starting points and study designs differ, so these numbers are not a head-to-head comparison.

What “two-thirds regained” actually means

The STEP 1 extension followed 327 participants, a subset of the original trial. At week 68, both the study medication and the structured lifestyle intervention ended. By week 120, the semaglutide group had regained roughly two-thirds of its earlier mean weight loss; several cardiometabolic measures also moved back toward baseline. Extension results.

Three details matter when applying this finding:

• It describes a group average, not every participant's trajectory.
• The denominator is the weight previously lost, not total body weight.
• Medication and structured lifestyle support ended together, so the extension cannot isolate every contributor to regain.

The study is evidence that follow-up matters. It is not a forecast of an individual reader's future weight.

What SURMOUNT-4 adds

After the tirzepatide lead-in, 670 participants were randomized to continued treatment or placebo. They had obesity or overweight with a weight-related complication, without diabetes. The trial compared continuation with withdrawal among people who reached that point in treatment. Trial report.

The 14.0% regain figure uses weight at randomization, after the initial loss, as its reference. STEP 1's 11.6-percentage-point figure uses original baseline weight. Treating those as interchangeable units would produce a misleading comparison.

Together, the studies support discussing obesity treatment as an ongoing care plan. They do not establish that one specific medicine, dose or duration is right for every person.

Does tapering prevent regain?

These two trials do not establish a tapering schedule that prevents regain. Neither provides evidence for an internet protocol of progressively smaller doses, pen-click adjustments or a supplement replacement.

A clinician may alter treatment for reasons such as adverse effects, pregnancy plans, access or changing health needs. That decision is separate from claiming that a particular taper has been proven to preserve the original weight loss. Ask what evidence supports a proposed strategy and how outcomes will be monitored.

Our Mounjaro dosage guide explains why a short missed-dose rule is not a restart plan after a longer interruption. For pregnancy-related decisions, see the separate pregnancy explainer and discuss the actual medicine with the care team.

A useful follow-up conversation

Before a planned interruption, write down the reason treatment may stop and the practical problem that needs solving. Examples include refill access, side effects, costs or a new health circumstance. Then ask:

1. Which benefits besides weight need reassessment, such as glucose control?
2. When should follow-up take place, and what changes should prompt earlier contact?
3. What nutrition and activity support is realistic for my health and daily routine?
4. Are there appropriate treatment alternatives if the original medicine cannot continue?
5. If restarting is considered later, who will specify the dose and timing?

For meal organization, our free beginner meal-planning guide offers a grocery-list workflow. It is a practical resource, not a tested method for preventing post-treatment regain. Products marketed as weight-loss supplements also need separate evidence; they should not be assumed to reproduce medication effects.

Sources and revision

Primary sources checked September 15, 2026: Wilding and colleagues, STEP 1 extension and Aronne and colleagues, SURMOUNT-4. This revision corrects the extension sample size, distinguishes percentage points from percentage changes, and removes unsupported promises about tapering. Editorial synthesis with AI assistance; no independent physician review is claimed.